Brevitest Technologies Becomes First Remote Resident of Baltimore’s LaunchPort™ Manufacturing Accelerator
- No Comments
The LaunchPort™ announced today that Brevitest Technologies will become the latest out-of-state company to partner with the device accelerator. Brevitest has developed a point-of-care analyzer capable of accurately performing enzyme-linked immunosorbent assays (ELISAs), the gold standard for measuring concentrations of molecules in solution. Unlike ELISAs done in laboratories, the technology is portable with a run time of less than 15 minutes. Developed as a platform technology, capable of performing a wide variety of tests with laboratory-quality sensitivity and specificity, the assays are targeted at numerous clinical, forensic, environmental and lifestyle applications. The newest version of the device is currently undergoing review to allow rapid point-of-care COVID-19 testing. The unique nature of the relationship – which involves both LaunchPort and Engineering Medical Systems – gives Brevitest immediate access to design control and manufacturing protocols that will allow their internal development team to convert the functional prototypes to a marketable product in a little over a month. Simultaneously, those reviews are preparing the product for the eventual broader launch into opioid testing and other infectious diseases.
News Article